Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

Sanofi

Status and phase: Completed; Phase 4

Conditions: Prostatic Neoplasms

Treatments: Drug: docetaxel

Study type: Interventional

Funder types: Industry

Identifiers

NCT00280098

XRP6976J_4001

Details and patient eligibility

About

Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.

Enrollment: 30 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Main criteria are listed hereafter :

Inclusion Criteria:

• Patients with advanced prostate cancer, without previous chemotherapy, progressing on hormonal treatment, performance status 1 to 2

Exclusion Criteria:

• Other cytostatic treatment, other malignity, severe comorbidity

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

single group

Experimental group

Treatment:

Drug: docetaxel